

Jun Ho Jang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1160078/publications.pdf>

Version: 2024-02-01

108
papers

2,200
citations

394421

19
h-index

233421

45
g-index

108
all docs

108
docs citations

108
times ranked

3111
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 311-318.	1.1	6
2	<i>IDH1/2</i> mutations in acute myeloid leukemia. <i>Blood Research</i> , 2022, 57, 13-19.	1.3	6
3	Management of immune thrombocytopenia: 2022 update of Korean experts recommendations. <i>Blood Research</i> , 2022, 57, 20-28.	1.3	10
4	Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. <i>Journal of Clinical Oncology</i> , 2022, 40, 855-865.	1.6	86
5	Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. <i>European Journal of Haematology</i> , 2022, 109, 205-214.	2.2	19
6	Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 48-56.	1.6	80
7	Association between body image dissatisfaction and poor quality of life and depression among patients with hematopoietic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2021, 29, 3815-3822.	2.2	10
8	Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 413-423.	1.7	4
9	Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms. <i>Journal of Clinical Oncology</i> , 2021, 39, 7011-7011.	1.6	3
10	LSAMP Rearrangement in Acute Myeloid Leukemia With a Jumping Translocation Involving 3q13.31. <i>Annals of Laboratory Medicine</i> , 2021, 41, 342-345.	2.5	1
11	Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine. <i>Journal of Clinical Oncology</i> , 2021, 39, 7018-7018.	1.6	6
12	Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34 ⁺ cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2021, 36, 737-749.	1.3	2
13	Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. <i>Haematologica</i> , 2021, 106, 3240-3244.	3.5	6
14	Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial. <i>Blood</i> , 2021, 138, 871-871.	1.4	8
15	A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3425-3425.	1.4	0
16	Efficacy and Safety of Eltrombopag Combined with Cyclosporine As First-Line Therapy in Adults with Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm Soar Study. <i>Blood</i> , 2021, 138, 2174-2174.	1.4	1
17	Therapy-related myeloid neoplasms after transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>Blood Research</i> , 2021, 56, 349-353.	1.3	1
18	Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults. <i>Annals of Laboratory Medicine</i> , 2020, 40, 88-91.	2.5	1

#	ARTICLE	IF	CITATIONS
19	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. <i>PLoS Medicine</i> , 2020, 17, e1003091.	8.4	9
20	Getting patient blood management Pillar 1 right in the Asia-Pacific: a call for action. <i>Singapore Medical Journal</i> , 2020, 61, 287-296.	0.6	6
21	Health-related quality of life (HRQoL) in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy (IC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 7533-7533.	1.6	4
22	Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. <i>International Journal of Hematology</i> , 2019, 110, 411-418.	1.6	9
23	Comparison of quality of life and depression between hematopoietic stem cell transplantation survivors and their spouse caregivers. <i>Blood Research</i> , 2019, 54, 137-143.	1.3	5
24	Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 656-664.	0.4	5
25	Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis. <i>Annals of Hematology</i> , 2019, 98, 2273-2281.	1.8	2
26	Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e562-e572.	4.6	30
27	Anti-leukemic effects of simvastatin on NRASG12D mutant acute myeloid leukemia cells. <i>Molecular Biology Reports</i> , 2019, 46, 5859-5866.	2.3	12
28	Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e122-e131.	4.6	20
29	Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry. <i>American Journal of Hematology</i> , 2019, 94, E37-E41.	4.1	17
30	Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL. <i>Blood</i> , 2019, 134, 5069-5069.	1.4	0
31	Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population. <i>Leukemia Research</i> , 2018, 69, 31-38.	0.8	5
32	Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study. <i>Bone Marrow Transplantation</i> , 2018, 53, 967-976.	2.4	14
33	Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. <i>Blood Advances</i> , 2018, 2, 2176-2185.	5.2	65
34	Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia. <i>Annals of Laboratory Medicine</i> , 2018, 38, 495-502.	2.5	5
35	A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine. <i>Oncotarget</i> , 2018, 9, 6607-6614.	1.8	7
36	Prospective phase II pilot study to evaluate the use of intravenous iron in the treatment of anemia in cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10113-10113.	1.6	0

#	ARTICLE	IF	CITATIONS
37	BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. <i>Haematologica</i> , 2017, 102, e187-e190.	3.5	13
38	Atypical presentations of MERS-CoV infection in immunocompromised hosts. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 769-773.	1.7	36
39	Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma. <i>Nutrition</i> , 2017, 36, 67-71.	2.4	20
40	Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. <i>Blood Research</i> , 2017, 52, 207.	1.3	11
41	Management of immune thrombocytopenia: Korean experts recommendation in 2017. <i>Blood Research</i> , 2017, 52, 254.	1.3	20
42	Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. <i>BMC Cancer</i> , 2017, 17, 852.	2.6	57
43	Clinical manifestation and prognostic features of extramedullary plasmacytomas. <i>Journal of Clinical Oncology</i> , 2017, 35, e19516-e19516.	1.6	1
44	Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab. <i>Blood Research</i> , 2016, 51, 297.	1.3	2
45	Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. <i>Journal of Korean Medical Science</i> , 2016, 31, 214.	2.5	51
46	Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. <i>Journal of Infection</i> , 2016, 73, 496-505.	3.3	34
47	Cytogenetic profiles of 2806 patients with acute myeloid leukemia—a retrospective multicenter nationwide study. <i>Annals of Hematology</i> , 2016, 95, 1223-1232.	1.8	14
48	Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia. <i>International Journal of Hematology</i> , 2016, 103, 44-52.	1.6	8
49	Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study. <i>Annals of Hematology</i> , 2016, 95, 337-344.	1.8	22
50	Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis. <i>Annals of Hematology</i> , 2016, 95, 325-335.	1.8	36
51	Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry. <i>Annals of Hematology</i> , 2016, 95, 125-133.	1.8	14
52	Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC) Tj ETQq0 0 0.1gBT /Overlock 10 T		
53	Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement-Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation Study. <i>Blood</i> , 2016, 128, 2428-2428.	1.4	9
54	Longitudinal Tracking of MDS Patients Using Next Generation Sequencing Provides a Predictive Measure for Azacitidine Response and AML Progression. <i>Blood</i> , 2016, 128, 52-52.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Killer Cell Immunoglobulin-like Receptor Ligand Matching Determines the Post-Transplant High Risk Groups Among Patients with Permissive HLA Mismatch in Unrelated Donor Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 4566-4566.	1.4	0
56	Measurement of Quality of Life and Depression of Spouse Caregivers for Survivors after Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 4775-4775.	1.4	0
57	Replication of New Genomic Classification System in Acute Myeloid Leukemia with Normal Karyotype. <i>Blood</i> , 2016, 128, 2876-2876.	1.4	0
58	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , 2015, 35, 2363-2369.	3.9	21
59	Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. <i>Oncotarget</i> , 2015, 6, 42803-42812.	1.8	23
60	International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. <i>Blood</i> , 2015, 126, 291-299.	1.4	982
61	A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2015, 102, 401-412.	1.6	13
62	Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. <i>Lancet Haematology</i> , 2015, 2, e417-e426.	4.6	64
63	KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study. <i>Human Immunology</i> , 2015, 76, 636-643.	2.4	11
64	Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients. <i>Oncotarget</i> , 2015, 6, 16653-16662.	1.8	17
65	A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. <i>Oncotarget</i> , 2015, 6, 44985-44994.	1.8	17
66	Dyadic Concordance of Sexuality Among Hematopoietic Stem Cell Transplantation Patients and Their Partners. <i>Blood</i> , 2015, 126, 4349-4349.	1.4	0
67	Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients. <i>Blood</i> , 2015, 126, 1904-1904.	1.4	0
68	Clinical Relevance of Failure to Achieve Early Molecular Response in Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , 2015, 126, 5160-5160.	1.4	0
69	Comparable Outcomes with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients with or without Aplastic Anemia in a Prospective Korean PNH Registry. <i>Blood</i> , 2015, 126, 4789-4789.	1.4	0
70	Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome. <i>Anticancer Research</i> , 2015, 35, 3081-9.	1.1	25
71	Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 61.	2.5	4
72	Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	18

#	ARTICLE	IF	CITATIONS
73	Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial. <i>Blood</i> , 2014, 124, 10-10.	1.4	11
74	Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study. <i>Blood</i> , 2014, 124, 621-621.	1.4	8
75	Clinical relevance of genetic mutations on treatment response to the demethylating agents in myelodysplastic syndromes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7115-7115.	1.6	0
76	Evaluation of biochemical features of anemia in cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20698-e20698.	1.6	1
77	A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes. <i>Blood</i> , 2014, 124, 4642-4642.	1.4	0
78	Ineffective Corticosteroid Treatment for Hemolysis Management of Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2014, 124, 5151-5151.	1.4	0
79	a Randomized, Controlled, Prospective Study for Efficacy of Micafungin Versus Itraconazole As Empirical Antifungal Therapy for Febrile Neutropenic Patients with Acute Leukemia. <i>Blood</i> , 2014, 124, 3729-3729.	1.4	0
80	Renal Insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement. <i>Anticancer Research</i> , 2014, 34, 4299-306.	1.1	10
81	Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. <i>International Journal of Hematology</i> , 2013, 97, 749-757.	1.6	98
82	Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload. <i>Journal of Korean Medical Science</i> , 2013, 28, 1563.	2.5	10
83	The Clinical Significance Of Activated p-AKT Expression In Peripheral T-Cell Lymphomas. <i>Blood</i> , 2013, 122, 4315-4315.	1.4	0
84	Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry. <i>Blood</i> , 2013, 122, 3720-3720.	1.4	1
85	Impact Of High Resolution HLA Mismatch On Outcomes Of Unrelated Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 5534-5534.	1.4	0
86	Post-Transplant Immune Monitoring In Patients Receiving Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 5486-5486.	1.4	0
87	Non Malignant Late Complications After Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT); Korean Experience. <i>Blood</i> , 2012, 120, 4462-4462.	1.4	0
88	Comparison of BuCy (Busulfan plus Cyclophosphamide) Versus FluBu4 (Fludarabine plus Busulfan) As a Conditioning Regimen for Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4522-4522.	1.4	0
89	Risk of Thromboembolism in Patients with Paroxysmal Nocturnal Hemoglobinuria Presenting with Both Clinical Symptoms and Elevated Hemolysis. <i>Blood</i> , 2012, 120, 1273-1273.	1.4	0
90	Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2011, 93, 383-388.	1.6	21

#	ARTICLE	IF	CITATIONS
91	Uncontrolled Complement Activation and the Resulting Chronic Hemolysis As Measured by LDH Serum Level At Diagnosis As Predictor of Thrombotic Complications and Mortality in a Large Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).. Blood, 2011, 118, 3166-3166.	1.4	7
92	Acute Myeloid Leukemia with Myelodysplasia-Related Changes (MRC) Did Not Show Inferior Outcomes Compared to Those without MRC.. Blood, 2011, 118, 3563-3563.	1.4	0
93	Baseline Quality of Life Assessed with the EORTC QLQ-C30 Predicts the Treatment Outcome of Patients with Diffuse Large B-Cell Lymphoma: Results of a Prospective Cohort Study. Blood, 2011, 118, 1595-1595.	1.4	0
94	Impact of Severe Pain on Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2011, 118, 5273-5273.	1.4	0
95	Genome-Wide Single-Nucleotide Polymorphism-Array Based Karyotyping Detects Clonal Aberrations Including Uniparental Disomy (UPD), Gain or Loss Which Were Unfavorable Prognostic Factor In Acute Myeloid Leukemia with Normal Karyotype.. Blood, 2010, 116, 1669-1669.	1.4	8
96	A 2-Year Single Center Experience of Decitabine Treatment for the Patients with MDS and CMML. Blood, 2010, 116, 4952-4952.	1.4	0
97	Dasatinib for Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib In Korean Patients.. Blood, 2010, 116, 4494-4494.	1.4	0
98	Secondary Acute Myeloid Leukemia (AML), Including Therapy-Related AML, Associates with Worse Treatment Outcomes, Than De Novo AML Even After Hematopoietic Stem Cell Transplantation, and Its Unfavorable Behavior Does Not Associated with Functional Activity of p-Glycoprotein, MDR1. Blood, 2010, 116, 2157-2157.	1.4	0
99	Addition of Hemoglobin Level Into the Prognostic Scoring System Together with White Blood Cell and Platelet Count Provides Better Prognostic Stratification for Treatment-Related Mortality and Overall Survival, but Not for Relapse Risk In Adult Patients with Acute Promyelocytic Leukemia. Blood, 2010, 116, 4371-4371.	1.4	0
100	Pharmacogenomics-Based Drug Response Prediction Model for Acute Myeloid Leukemia with Normal Karyotype. Blood, 2010, 116, 2698-2698.	1.4	0
101	Efficacy and Safety of Micafungin as An Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases.. Blood, 2009, 114, 4661-4661.	1.4	0
102	Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea.. Blood, 2009, 114, 4298-4298.	1.4	0
103	Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia.. Blood, 2009, 114, 1110-1110.	1.4	8
104	Relapsed Intravascular Large B-cell Lymphoma in the Lungs. The Korean Journal of Hematology, 2008, 43, 113.	0.7	0
105	Do Microenvironmental Factors Play Important Role in Supporting the Maintenance of Leukemic Stem Cells of Chronic Myelogenous Leukemia?. Blood, 2008, 112, 4219-4219.	1.4	0
106	Neutrophil Counts Could Predict the Response to Immunosuppressive Treatment with Antithymocyte Globulin and Cyclosporine in the Patients with Severe Aplastic Anemia. Blood, 2008, 112, 4109-4109.	1.4	8
107	The Optimal Processing Time of Adipose-Derived Mesenchymal Stem Cell after Lipoaspiration.. Blood, 2007, 110, 4107-4107.	1.4	0
108	Prediction of Survival in Patients with Myelodysplastic Syndrome According to WHO Classification-Based Prognostic Scoring System (WPSS).. Blood, 2007, 110, 4617-4617.	1.4	0